Navigation Links
Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting

cipates will occur in the future and include, but are not limited to, earnings estimates, statements that are not historical facts relating to Neurogen's future financial performance, its growth and business expansion, its financing plans, the timing and occurrence of anticipated clinical trials, and potential collaborations or extensions of existing collaborations. These statements are based on certain assumptions made by Neurogen based on its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. Actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various factors, including, but not limited to, risks associated with the inherent uncertainty of drug research and development, difficulties or delays in development, testing, regulatory approval, production and marketing of any of Neurogen's drug candidates, adverse side effects or inadequate therapeutic efficacy or pharmacokinetic properties of Neurogen's drug candidates or other properties of drug candidates which could make them unattractive for commercialization, advancement of competitive products, dependence on corporate partners, Neurogen's ability to retain key employees, sufficiency of cash to fund Neurogen's planned operations and patent, product liability and third party reimbursement risks associated with the pharmaceutical industry. Although Neurogen believes that its expectations are based on reasonable assumptions, it can give no assurance that the anticipated results will occur. For such statements, Neurogen claims the protection of applicable laws. Future results may also differ from previously reported results. For example, positive results or safety and tolerability in one clinical study provides no assurance that this will be true in future studies. Forward-looking statements represent the judgment of Neurogen's management
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
2. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
3. Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
4. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
5. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
6. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
7. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
8. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
9. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
10. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
11. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:5/29/2015)... 28, 2015 Research and Markets ( http://www.researchandmarkets.com/research/64lx2w/north_america_mri ... America MRI Market - Growth, Trends And Forecasts (2014 ... The North American MRI systems market is estimated to ... $1.58 billion by 2020 with a CAGR of 2.9% ... types namely, the open system, closed system and the ...
(Date:5/29/2015)... DUBLIN , May 28, 2015 Research ... of the "North America Open System MRI Market ... report to their offering. The key players ... , Philips Healthcare, Siemens Healthcare and Toshiba Medical Systems ... tool which is replacing CT because of its higher ...
(Date:5/29/2015)... , May 29, 2015  The annual customer satisfaction ... ranks Praxis EMR as #1 across all specialties. Every ... Research LLC conducts a poll of EHR users and ... results.    Praxis EMR topped 348 ... 18 performance based criteria used by Black Book. In ...
Breaking Medicine Technology:North America MRI Market - Growth, Trends And Forecasts 2014-2019 with GE, Hitachi Medical, Philips Healthcare, Siemens Healthcare & Toshiba Medical Systems Dominating 2North America Open System MRI Market 2014-2019 with GE, Hitachi Medical, Philips Healthcare, Siemens Healthcare and Toshiba Medical Dominating 2Praxis EMR Ranks #1 for Physician Satisfaction in Black Book's 2015 Survey of Solo and Small Practices 2
... RDEA594 Data to Be Presented at the 2008 Annual European Congress of, Rheumatology ... Phase 1 Human Study of RDEA594 Planned in Second Half of ... ... Biosciences, Inc.,(Nasdaq: RDEA ) today announced the identification of its lead development,candidate ...
... filing anticipated in 1Q 2009 -, PRINCETON, ... ) has nominated PSI-7851 as a lead development ... (HCV). PSI-7851 is a proprietary,nucleotide analogue polymerase inhibitor ... Practice (GLP) animal toxicity studies required for,submission of ...
Cached Medicine Technology:Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 2Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 3Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 4Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 5Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C 2Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C 3
(Date:5/29/2015)... New York, NY (PRWEB) May 29, 2015 ... Pharmaceuticals unit have reached a confidential Risperdal lawsuit ... who allegedly developed gynecomastia due to his use ... the case had been selected for the third ... in a mass tort litigation underway in Pennsylvania’s ...
(Date:5/29/2015)... Inspire Nexus, a new social network officially ... question many life coaches have asked, "How do I ... necessary to become a credentialed Coach?" , Many Life ... for long. Inspire Nexus, a social network for Coaches ... who have experience coaching a certain number of hours, ...
(Date:5/29/2015)... Chicago, Ill (PRWEB) May 29, 2015 ... Care , a dozen medical pioneers recognized by a ... changed the course of cancer treatment. Honorees will be ... of Cancer Care™ Award Ceremony, held 8:30-11:00 p.m. CDT ... , The 2015 honorees are being recognized for groundbreaking ...
(Date:5/29/2015)... 2015 The Global Allopurinol Industry ... on the current state of the Allopurinol industry.With ... statistics on the state of the industry and ... for companies and individuals interested in the market. ... industry including definitions, classifications, applications and industry chain ...
(Date:5/29/2015)... May 29, 2015 Healthpointe’s electromyography ... to the Los Angeles County clinics including its ... are now being offered at all Healthpointe locations ... and San Bernardino County. , As the ... send electrical impulses throughout the body and ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 2Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 3Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 4Health News:Allopurinol Industry (Global, China) 2015 Research Analysis and 2020 Forecasts 2Health News:Healthpointe Is Now Offering EMG and NCV Diagnostics at All Clinics throughout Southern California. 2
... a scientist with Lawson Health Research Institute in London, Ontario ... North America and around the world. Matic has been ... gum tissue of cleft palate patients. His research suggests that ... , Matic is a craniofacial/plastic surgeon at London Health Sciences ...
... 750,000, mostly males, are hooked , , MONDAY, May 12 ... young adults are problem gamblers according to researchers at ... , Problem gambling is defined as gambling associated with ... than you intended or stealing money to gamble. , ...
... May 12 OmniSonics Medical,Technologies, Inc., a developer ... of vascular disease, announced today that it has ... SONIC II is a prospective,multi-center U.S. registry study ... undergoing percutaneous mechanical thrombectomy,for acute limb ischemia (ALI). ...
... Naturlose, a natural sugar,approved as a food ingredient in ... of serum glucose that follow consumption of food (1). In,a ... is currently,studying the efficacy and safety of Naturlose for the ... has engaged market,research companies to seek feedback as to the ...
... Reporters/Editors/Producers , RE: American Psychological Association 116th Annual Convention ... Room 162A, Meeting Level 1, Boston Convention and Exhibition ... lap tops and two high-speed printers. We will also ... data transmission and APA staff resources. This room will ...
... Joel Ario today announced that the Insurance Department ... the state to,hear from consumers and other affected ... and Independence Blue Cross, plus related,changes, will impact ... held July 8 in Pittsburgh, July 10 in ...
Cached Medicine News:Health News:Research shows timing improves cleft palate surgery 2Health News:Problem Gambling Common Among Young Adults 2Health News:OmniSonics Medical Technologies Announces First Patient Enrolled in SONIC II REGISTRY 2Health News:Market Research Shows Spherix's Naturlose(R) Readily Accepted by Diabetes Patients 2Health News:Market Research Shows Spherix's Naturlose(R) Readily Accepted by Diabetes Patients 3Health News:Highlights for APA's 116th Annual Convention in Boston, Aug. 14-17 2Health News:Highlights for APA's 116th Annual Convention in Boston, Aug. 14-17 3Health News:Highlights for APA's 116th Annual Convention in Boston, Aug. 14-17 4Health News:Insurance Department to Hold Statewide Meetings on Proposed Consolidation of Independence Blue Cross, Highmark 2
The Benchmark Microplate Reader, with its increased wavelength range of 340 to 750 nm and high performance optics, provides flexibility for specialized applications requiring increased linearity, ult...
Plate Reader is an eight channel photometer for the sequential and simultaneous reading of micro-plate strips with 96 wells. High technology, user friendly, powerful and reliable....
TC-98 elisa strip reader. Reads, calculates, and prints results for up to 12 wells in about 30 seconds. Single point calibration. Multi-point calibration....
Stat Fax 2200 Incubator shaker....
Medicine Products: